| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.decipherlabs.in/ | |
| Market Cap | 49.89 Cr. | |
| Enterprise Value(EV) | 60.22 Cr. | 2022-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 11.27 | Trailing Twelve Months Ending 2022-03 |
| Price-Earning Ratio (PE) | 4.38 | Trailing Twelve Months Ending 2022-03 |
| Industry PE | 28.07 | Trailing Twelve Months Ending 2022-03 |
| Book Value / Share | 23.93 | Trailing Twelve Months Ending 2022-03 |
| Price to Book Value | 2.06 | Calculated using Price: 49.40 |
| Dividend Yield | 0.00 | Period Ending 2021-03 |
| No. of Shares Subscribed | 1.01 Cr. | 10,100,000 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Combat is a professionally managed, well established public limited company, engaged in the manufacture & marketing of Pharmaceutical Formulations since its incorporation in 1986. The company has been marketing its branded formulations and entering into agreements with various companies for custom manufacturing and has grown to be known as a quality provider. During the years of operations, the products of the company have been well accepted by the Trade and Medical Fraternity across India.Playing a key role in promoting and sustaining development in the vital field of Pharmaceuticals, Combat Drugs boasts of quality fixed dosage formulations manufactured in multiple locations with GMP & WHO cGMP certification and certified through a well designed Quality Assurance Program, approved by regulatory authorities in India. Quality, Efficacy & Service are the three key words in the company’s motto in providing succor to the ailing Humanity by producing high quality medicines at an affordable cost for combating life threatening Diseases and improving the global standards of health. In order to achieve this objective, the company lays emphasis on implementing total Quality Assurance of its formulations by inculcating the principles of Good Manufacturing Practices among its staff members at all levels. Some of the Key Highlights in making Combat a preferred supplier to the consumer as well as the medical fraternity are: • An Un-compromised commitment towards quality. Busines area of the company: The company is engaged in the manufacture & marketing of Pharmaceutical Formulations. Products: Combat is engaged in the manufacturing and marketing of its branded Pharmaceutical Formulations in the following mentioned forms and methods: a) Solid dosage forms: Unit dose form(Tablets, Capsules): Single Ingredient / Multi Ingredient, Plain, Film, Sugar & Enteric Coated, Patent & Proprietary Tablets of various sizes; shapes and colors. And Single and Multi ingredient capsules. b) Liquid dosage forms: Liquid Orals as Single Ingredient and Multi Ingredient in various measures as desired by the buyer. c) Ointments: Various Combinations of Ointments |
||
Company Profile
Combat is a professionally managed, well established public limited company, engaged in the manufacture & marketing of Pharmaceutical Formulations since its incorporation in 1986. The company has been marketing its branded formulations and entering into agreements with various companies for custom manufacturing and has grown to be known as a quality provider.
During the years of operations, the products of the company have been well accepted by the Trade and Medical Fraternity across India.Playing a key role in promoting and sustaining development in the vital field of Pharmaceuticals, Combat Drugs boasts of quality fixed dosage formulations manufactured in multiple locations with GMP & WHO cGMP certification and certified through a well designed Quality Assurance Program, approved by regulatory authorities in India.
Quality, Efficacy & Service are the three key words in the company’s motto in providing succor to the ailing Humanity by producing high quality medicines at an affordable cost for combating life threatening Diseases and improving the global standards of health. In order to achieve this objective, the company lays emphasis on implementing total Quality Assurance of its formulations by inculcating the principles of Good Manufacturing Practices among its staff members at all levels.
Some of the Key Highlights in making Combat a preferred supplier to the consumer as well as the medical fraternity are:
• An Un-compromised commitment towards quality.
• Competitively priced solutions.
• Technologically strong and totally self-reliant.
• Vast experience and technical know-how
• The right product-mix for sustained future growth.
• Well known brands with high market penetration.
• Extensive distribution network with an all India presence.
Busines area of the company:
The company is engaged in the manufacture & marketing of Pharmaceutical Formulations.
Products:
Combat is engaged in the manufacturing and marketing of its branded Pharmaceutical Formulations in the following mentioned forms and methods:
a) Solid dosage forms: Unit dose form(Tablets, Capsules): Single Ingredient / Multi Ingredient, Plain, Film, Sugar & Enteric Coated, Patent & Proprietary Tablets of various sizes; shapes and colors. And Single and Multi ingredient capsules.
b) Liquid dosage forms: Liquid Orals as Single Ingredient and Multi Ingredient in various measures as desired by the buyer.
c) Ointments: Various Combinations of Ointments
| 1 Day |
|
-4.91% |
| 1 Week |
|
+4.55% |
| 1 Month |
|
-8.26% |
| 3 Month |
|
-31.34% |
| 6 Month |
|
+29.15% |
| 1 Year |
|
+43.60% |
| 2 Year |
|
+143.95% |
| 5 Year |
|
+321.86% |
| 10 Year |
|
| 4 years | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | 8.60 | 17.45 | 14.59 | 10.69 | |
| Return on Capital Employed (%) | 8.10 | 17.95 | 18.11 | 13.09 | |
| Return on Assets (%) | 6.16 | 8.71 | 5.28 | 3.79 |
| Particulars | 5 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03* Rs. Cr. |
| Shh. Funds | 2 | 3 | 13 | 14 | 24 | |
| Non Curr. Liab. | 1 | 8 | 7 | |||
| Curr. Liab. | 1 | 4 | 21 | 17 | 11 | |
| Minority Int. | ||||||
| Equity & Liab. | 3 | 6 | 35 | 39 | 42 | |
| Non Curr. Assets | 0 | 13 | 16 | 4 | ||
| Curr. Assets | 3 | 6 | 23 | 23 | 38 | |
| Misc. Exp. not W/O | ||||||
| Total Assets | 3 | 6 | 35 | 39 | 42 |
| Particulars | 5 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. TTM |
| Net Sales | 1 | 8 | 24 | 56 | 65 | |
| Other Income | 0 | 0 | 1 | 8 | ||
| Total Income | 1 | 8 | 24 | 56 | 73 | |
| Total Expenditure | -1 | -8 | -21 | -52 | -59 | |
| PBIDT | 0 | 0 | 3 | 4 | 14 | |
| Interest | 0 | -1 | -1 | 0 | ||
| Depreciation | -1 | -1 | -1 | |||
| Taxation | 0 | 0 | -1 | -1 | ||
| Exceptional Items | ||||||
| PAT | 0 | 0 | 1 | 1 | 11 | |
| Minority Interest | ||||||
| Share Associate | ||||||
| Other Related Items | ||||||
| Consolidated Net Profit | 0 | 0 | 1 | 1 | 11 | |
| Adjusted EPS | 0 | 1 | 1 | 1 | 11 |
| Particulars | 4 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | 0 | 0 | -15 | 2 | |
| Cash Fr. Inv. | 0 | 0 | 0 | ||
| Cash Fr. Finan. | 0 | 0 | 16 | 4 | |
| Net Change | 0 | 0 | 1 | 6 | |
| Cash & Cash Eqvt | 0 | 0 | 1 | 7 |
|
Wed, 18 May 2022
Announcement under Regulation 30 (LODR)-Meeting Updates Meeting Updates |
|
Wed, 18 May 2022
Announcement under Regulation 30 (LODR)-Newspaper Publication Intimation-Newspaper Publication of Notice of Audited Financial Results (Standalone & Consolidated) for Quarter and Year ended 31.03.2022 |
|
Mon, 16 May 2022
Audited Financial Results (Standalone And Consolidated) For The Quarter And Year Ended 31.03.2022 Audited Financial Results (Standalone and consolidated) for the quarter and year ended 31.03.2022 |
| Wed, 25 May 2022 |
Close Crossing Last Month Low
|
Closing Below Previous Low
|
High Decrease 1 Month
|
High Decrease 3 Months
|
High Increase 6 Months
|
Equities
M.F.
Sectors